Erfonrilimab
As of the edition of 20 October 2026, Erfonrilimab is an antibody: in active development; acts on CD274 and CTLA4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Antibody
- Registered trials
- 27, 7 stopped early
- Disease areas
- Cancer; Digestive system; Blood and lymph; Hormones; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of Erfonrilimab.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 20 | 4 | 5 | 6 |
| Phase 3 | 4 | 0 | 0 | 1 |
| All trials | 27 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Alphamab | Lead sponsor of trials | 2018 to now |
| Jiangsu Alphamab Biopharmaceuticals | Lead sponsor of trials | 2018 to now |
| Suzhou Zelgen Biopharmaceuticals | Lead sponsor of trials | 2021 to now |
| Suzhou Kintor Pharmaceutical | Lead sponsor of trials | 2021 to now |
| InxMed | Lead sponsor of trials | 2022 to now |
| Zhejiang Raygene Pharmaceuticals | Lead sponsor of trials | 2023 to now |